Diffuse Large B-Cell Lymphoma Test Your Knowledge

Test Your Knowledge

Quiz: Polatuzumab Vedotin Plus Bendamustine and Rituximab in R/R DLBCL

12/02/2021

True or false: Polatuzumab vedotin plus bendamustine and rituximab shows safety in patients with R/R DLBCL.

True or false: Polatuzumab...

12/02/2021

Oncology

Test Your Knowledge

Quiz: Is This Acalabrutinib Combo Safe for Patients With R/R DLBCL?

11/15/2021

True or false: Acalabrutinib plus AXD9150 is safe and tolerable for patients with R/R DLBCL, but has limited efficacy.

True or false: Acalabrutinib...

11/15/2021

Oncology

Test Your Knowledge

Quiz: Does Tafasitamab Show Tolerability in DLBCL?

11/11/2021

True or false: Tafasitamab with or without lenalidomide and R-CHOP are both tolerable regimens for patients with DLBCL.

True or false: Tafasitamab with...

11/11/2021

Oncology

Test Your Knowledge

Quiz: What Combo Regimen Shows a Promising Safety Profile in DLBCL?

11/09/2021

Which of the following combinations showed a promising safety profile in patients with DLBCL and other B-NHLs?

Which of the following...

11/09/2021

Oncology

Test Your Knowledge

Quiz: Is Glofitamab Plus R-CHOP Tolerable for Patients With NHL, DLBCL?

11/08/2021

True or false: Glofitamab plus R-CHOP has tolerable safety in R/R NHL and previously untreated DLBCL?

True or false: Glofitamab plus...

11/08/2021

Oncology

Test Your Knowledge

Quiz: What Impact Do SNPs Have on Previously Untreated Patients With FL/DLBCL?

08/16/2021

True or false: SNPs influence the activity of the FcγR genotype, but are not associated with response to rituximab/obinutuzumab plus chemo in treatment-naïve patients with advanced FL or DLBCL.

True or false: SNPs influence...

08/16/2021

Oncology

Test Your Knowledge

Quiz: Lenalidomide Plus R-CHOP in Patients With ABC-Type DLBCL

04/19/2021

Does adding lenalidomide to R-CHOP worsen outcomes in patients with activated B-cell-like DLBCL?

Does adding lenalidomide to...

04/19/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology